FY2025 EPS Estimates for Cytokinetics Boosted by Analyst

Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) - Analysts at Cantor Fitzgerald boosted their FY2025 earnings per share (EPS) estimates for shares of Cytokinetics in a research report issued to clients and investors on Thursday, March 27th. Cantor Fitzgerald analyst C. Duncan now anticipates that the biopharmaceutical company will earn ($4.98) per share for the year, up from their prior forecast of ($5.28). The consensus estimate for Cytokinetics' current full-year earnings is ($5.24) per share.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($1.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.29) by $0.03. The firm had revenue of $16.93 million during the quarter, compared to analyst estimates of $14.26 million.

Several other equities analysts have also weighed in on CYTK. Royal Bank of Canada increased their price objective on shares of Cytokinetics from $80.00 to $82.00 and gave the company an "outperform" rating in a research report on Wednesday, December 18th. Stifel Nicolaus initiated coverage on shares of Cytokinetics in a research report on Wednesday, January 22nd. They set a "buy" rating and a $80.00 price objective for the company. Morgan Stanley set a $67.00 price objective on Cytokinetics in a report on Friday, March 7th. Evercore ISI upgraded Cytokinetics to a "strong-buy" rating in a research note on Friday, February 7th. Finally, Citigroup began coverage on Cytokinetics in a report on Friday, February 7th. They set a "buy" rating and a $86.00 price target for the company. Two analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Cytokinetics presently has an average rating of "Moderate Buy" and a consensus target price of $82.00.

Remove Ads

Cytokinetics Stock Performance

CYTK traded up $0.27 during trading hours on Monday, reaching $40.52. The company's stock had a trading volume of 2,740,602 shares, compared to its average volume of 1,533,553. The company's 50-day moving average is $45.20 and its 200-day moving average is $49.17. Cytokinetics has a 52 week low of $37.46 and a 52 week high of $75.71. The firm has a market cap of $4.80 billion, a PE ratio of -7.53 and a beta of 0.95. The company has a debt-to-equity ratio of 5.93, a quick ratio of 9.28 and a current ratio of 9.28.

Institutional Investors Weigh In On Cytokinetics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. GF Fund Management CO. LTD. bought a new position in Cytokinetics in the 4th quarter valued at approximately $117,000. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. bought a new position in shares of Cytokinetics in the 4th quarter valued at $15,483,000. Vestal Point Capital LP boosted its holdings in shares of Cytokinetics by 56.7% during the 4th quarter. Vestal Point Capital LP now owns 2,350,000 shares of the biopharmaceutical company's stock valued at $110,544,000 after acquiring an additional 850,000 shares in the last quarter. Two Sigma Advisers LP boosted its holdings in shares of Cytokinetics by 5.4% during the 4th quarter. Two Sigma Advisers LP now owns 226,400 shares of the biopharmaceutical company's stock valued at $10,650,000 after acquiring an additional 11,700 shares in the last quarter. Finally, Teza Capital Management LLC bought a new stake in Cytokinetics during the 4th quarter worth $446,000.

Insider Transactions at Cytokinetics

In other Cytokinetics news, CEO Robert I. Blum sold 16,970 shares of Cytokinetics stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $43.44, for a total value of $737,176.80. Following the transaction, the chief executive officer now owns 364,181 shares in the company, valued at $15,820,022.64. The trade was a 4.45 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Andrew Callos sold 3,341 shares of the business's stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $43.27, for a total value of $144,565.07. Following the transaction, the executive vice president now directly owns 64,434 shares of the company's stock, valued at approximately $2,788,059.18. The trade was a 4.93 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 58,834 shares of company stock valued at $2,560,525. Company insiders own 3.40% of the company's stock.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.